In the last decades, the introduction of effective anti-HER2 agents has impressively improved the prognosis of patients with HER2+ BC, both in early and advanced disease settings.4-6 In the advanced disease setting, the CLEOPATRA trial demonstrated a consistent PFS and OS benefit by adding pertuzumab to trastuzumab and docetaxel in previously untreated patients with HER2+ BC.5 According to these data, the combination of pertuzumab, trastuzumab, and taxane-based chemotherapy has become the first-line standard of care for advanced HER2+ BC. Here, ERBB2 is linked to breast cancer.